Adverse outcomes in COVID-19 and diabetes: a retrospective cohort study from three London teaching hospitals
Chioma Izzi‐Engbeaya, Walter Distaso, Anjali Amin, Wei Yang, Oluwagbemiga Idowu, Julia Kenkre, Ronak J Shah, Evelina Woin, Christine Shi, Nael Alavi, Hala Bedri, Niamh Brady, Sophie Blackburn, Martina Eva Leczycka, Sanya Patel, Elizaveta Sokol, Edward Toke‐Bjolgerud, Ambreen Qayum, Mariana Abdel-Malek, David C. D. Hope, Nick Oliver, Vasiliki Bravis, Shivani Misra, Tricia Tan, Neil Hill, Victoria Salem
Abstract
INTRODUCTION: Patients with diabetes mellitus admitted to hospital with COVID-19 have poorer outcomes. However, the drivers of poorer outcomes are not fully elucidated. We performed detailed characterization of patients with COVID-19 to determine the clinical and biochemical factors that may be drivers of poorer outcomes. RESEARCH DESIGN AND METHODS: This is a retrospective cohort study of 889 consecutive inpatients diagnosed with COVID-19 between March 9 and April 22, 2020 in a large London National Health Service Trust. Unbiased multivariate logistic regression analysis was performed to determine variables that were independently and significantly associated with increased risk of death and/or intensive care unit (ICU) admission within 30 days of COVID-19 diagnosis. RESULTS: 62% of patients in our cohort were of non-white ethnic background and the prevalence of diabetes was 38%. 323 (36%) patients met the primary outcome of death/admission to the ICU within 30 days of COVID-19 diagnosis. Male gender, lower platelet count, advancing age and higher Clinical Frailty Scale (CFS) score (but not diabetes) independently predicted poor outcomes on multivariate analysis. Antiplatelet medication was associated with a lower risk of death/ICU admission. Factors that were significantly and independently associated with poorer outcomes in patients with diabetes were coexisting ischemic heart disease, increasing age and lower platelet count. CONCLUSIONS: In this large study of a diverse patient population, comorbidity (ie, diabetes with ischemic heart disease; increasing CFS score in older patients) was a major determinant of poor outcomes with COVID-19. Antiplatelet medication should be evaluated in randomized clinical trials among high-risk patient groups.